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ess: ipreston@tufts-nemSummary Sildenafil and inhaled nitric oxide (iNO) relax smooth muscle by
inhibiting the degradation and stimulating the production of cyclic guanosine
monophosphate, respectively. We compared the acute pulmonary vasodilator effects
of sildenafil, iNO, and epoprostenol and asked whether the combination of iNO with
sildenafil had additive pulmonary vasodilator effects. We assessed the effects of
extended use of sildenafil in a small cohort of patients. Twenty patients with
pulmonary arterial hypertension underwent an acute vasodilator trial with sildenafil
(all patients), iNO and iNO plus sildenafil (11), and epoprostenol (19). We also
provided sildenafil to patients who were ineligible for, or had clinical deterioration
on epoprostenol, treprostinil, or bosentan. Mean7SE pulmonary artery pressure
dropped by 1373%, 1974%, 1473%, and 2674% with epoprostenol, iNO, sildenafil,
and iNO+sildenafil, respectively. Cardiac index increased with epoprostenol and
sildenafil. A correlation was found between the effects of iNO and epoprostenol.
Nine out of ten patients who were started on long-term sildenafil treatment alone or
in combination with other vasodilators had symptomatic improvement. Three died of
right heart failure. In conclusion, sildenafil is a potent acute pulmonary vasodilator,
an effect that is potentiated by combination with iNO. Long-term therapy of
pulmonary hypertension with sildenafil alone or in combination with other agents
appears to be safe and well tolerated.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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Pulmonary arterial hypertension (PAH) increases
morbidity and shortens survival, both in its primary
form, and when associated with other conditions
such as connective tissue diseases (CTD) or humaned.
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well understood, but involves altered vascular
function characterized by vasoconstriction, smooth
muscle cell proliferation and vascular remodeling.1
Major therapeutic advances have occurred in
recent years, with the introduction of intravenous
epoprostenol,2 the subcutaneous prostacyclin ana-
log, treprostinil,3 and the oral endothelin antago-
nist, bosentan.4 Current treatment options have
limited efficacy, however, often leaving patients
with persisting pulmonary hypertension and func-
tional impairment. Consequently, there is a need
for new, more effective, less expensive, and safer
therapies.
Cyclic guanosine monophosphate (cGMP) is an
intracellular second messenger that has been
implicated in maintaining the low tone of the
normal pulmonary vascular bed.5 In experimental
forms of pulmonary hypertension, agents that
increase cGMP levels produce pulmonary vasodila-
tion.6,7 Such agents include phosphodiesterase 5
(PDE5) inhibitors, that block the action of PDE5, an
enzyme found abundantly in lung parenchyma
that metabolizes cGMP,8 and nitric oxide (NO),
the endothelium-derived vasodilator molecule
that stimulates soluble guanylate cyclase to pro-
duce cGMP.
In the current study, we hypothesized that
sildenafil (Pfizer Laboratories, New York, NY), a
selective PDE5 inhibitor that inhibits the degrada-
tion of cGMP and vasodilates pulmonary vessels in
various forms of experimental9–11 and clinical12–15
pulmonary hypertension, has synergistic vasodila-
tory effects with inhaled NO (iNO), that stimulates
cGMP production. In this prospective observational
study, we compared the pulmonary vasodilator
effects of sildenafil to those of iNO, epoprostenol,
and the addition of iNO to sildenafil in patients with
various forms of PAH. In addition, we tested the
hypothesis that sildenafil would have longer-term
beneficial actions when administered to 10 patients
with PAH as a single vasodilator agent or in
combination with different agents and monitored
symptoms of exertional dyspnea, 6min walk dis-
tance, cardiac echocardiograms and the occur-
rence of side effects.Methods
We screened all patients referred between April
2001 and May 2002 to the Pulmonary Hypertension
Centers at Rhode Island Hospital in Providence, RI
and Boston Medical Center in Boston, MA, who
underwent right-heart catheterization for PAH andprogressive symptoms of dyspnea. Patients were
included in the study if they had a resting mean
pulmonary artery pressure (mPAP)425mm Hg, a
pulmonary artery wedge pressure (PAWP) p15mm
Hg, and no evidence of active ischemic heart
disease based on symptoms and echocardiography,
and if indicated, cardiac stress test, or left heart
catheterization. Patients were excluded if they
had resting hypotension (systemic systolic blood
pressureo90mm Hg), a cardiac index (CI)o 2.0 L/
min/m2, were using nitrates, or had end-stage liver
or renal disease.
The study protocol was approved by the Institu-
tional Review Boards at Rhode Island Hospital
and Boston Medical Center, and each patient
gave written informed consent before entering
the study.Hemodynamic measurements
A Swan-Ganz catheter was inserted through an
internal jugular or subclavian vein under pressure,
or fluoroscopic guidance. The electrocardiogram,
pulmonary arterial pressure, right atrial pressure
and oxygen saturation were monitored continu-
ously. Systemic blood pressure was recorded with a
noninvasive blood pressure cuff every 5min. Car-
diac output (CO) was measured in triplicate by the
thermodilution technique (Cardiac Output Compu-
ter, Baxter Edwards). Cardiac index (CI) was
calculated as CO divided by the body surface area.
Pulmonary and systemic vascular resistances (PVR
and SVR, respectively) were calculated using
standard hemodynamic formulas.Acute vasodilator testing
After baseline hemodynamics were measured,
patients underwent acute vasodilator testing.
Patients at Rhode Island Hospital received the
following vasodilators: iNO, epoprostenol, sildena-
fil, and sildenafil combined with iNO. Patients at
Boston Medical Center received epoprostenol and
sildenafil. iNO was delivered through a tight fitting
mask in sequential concentrations of 5, 10 and
20 ppm, every 5min, as previously described.16,17
Owing to a risk of acute pulmonary edema
associated with iNO at concentrations 410 ppm,18
patients with CTD received iNO only at 5 and
10 ppm. Epoprostenol infusion was started at
1–2 ng/kg/min and the dose was increased by
1–2 ng/kg every 10–15min, until limiting side
effects (headache, nausea, vomiting, or systemic
hypotension) occurred. Oral sildenafil was adminis-
tered after iNO and epoprostenol in 2 doses, 50 and
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Acute and chronic effects of sildenafil 1503100mg 1 h apart. Dosing of sildenafil was based on
previous reports.11–15 As a precaution, the sildenafil
doses were halved in patients X65 years. The
second dose was withheld if the patient developed
systemic hypotension with the first dose (SBP
o90mm Hg). A washout period of 30min was
allowed between iNO and epoprostenol and be-
tween epoprostenol and sildenafil testings. In order
to assess the acute vasodilator response to combi-
nation therapy, patients at Rhode Island Hospital
also received iNO 90min after the last dose of
sildenafil, in the lowest concentration that pre-
viously produced the maximum vasodilator re-
sponse. Ninety minutes was chosen to permit
development of a maximal hemodynamic response
to sildenafil. Hemodynamic measurements were
performed at baseline and before each change in
vasodilator concentration, once stabilization had
occurred. Supplemental oxygen was administered20 Patients 
11 Patients 
(RIH) 
9 Patients 
(BMC)
Figure 1 Algorithm for acute vasodilator testing that gives n
parentheses represent number of patients in each group. Br
lower sildenafil dose; age465 years or SBPo90mm Hg.
IPAH ¼ idiopathic pulmonary arterial hypertension, CTD ¼
BMC ¼ Boston Medical Center, RIH ¼ Rhode Island Hospital.to maintain an oxygen saturation 490%. The
protocol algorithm is presented in Fig. 1.Long-term treatment with sildenafil
Patients were offered compassionate administra-
tion of sildenafil if they were ineligible for or
declined epoprostenol therapy, if they were dete-
riorating clinically using their current vasodilator
therapy and if they were not receiving concurrent
nitrate therapy. Sildenafil was added to pre-exist-
ing therapy, which was continued in combination.
Sildenafil was begun at a dose of 25mg twice daily,
to avoid systemic hypotension that, in our experi-
ence, is encountered occasionally with initial doses
of X50mg. The dose was then advanced every 3–4
days to 50–100mg three times daily, as tolerated,
while we monitored symptoms (dyspnea, chestIPAH(7)
iNO: 20ppm (7) 
Epoprostenol: 2-8ng/kg/min (7) 
Sildenafil: 25mg(1) [>65years old, 
  SBP<90]
50mg(1) [SBP<90] 
     150mg(5)
CTD(3)
iNO:  10ppm (3) 
Epoprostenol: 2-8ng/kg/min (3) 
Sildenafil: 50mg (1) [SBP<90] 
 150mg (2) 
Secondary PAH(1)
iNO: 20ppm (1) 
Epoprostenol: 2-8ng/kg/min (1) 
Sildenafil: 75mg (1) [>65years old]
IPAH(4)
Epoprostenol: 2-8ng/kg/min (3) 
Sildenafil:        75mg(2)[>65years old] 
       150mg(2) 
CTD(4)
Epoprostenol: 2-8ng/kg/min (4) 
Sildenafil:        150mg (4) 
Sickle Cell(1)
Sildenafil: 150mg(1) 
umber of patients receiving different doses. Numbers in
ackets indicate occurrence of conditions that prescribed
SBP ¼ systolic blood pressure, measured in mm Hg.
connective tissue disease, iNO ¼ inhaled nitric oxide,
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extremity edema), systemic blood pressure, cardi-
ac echocardiograms and 6min walk distances.19Statistical analysis
All values are presented as means7SE. Within
group, before and after treatment effects were
analyzed using paired t-tests. For serial measure-
ments of hemodynamics of patients receiving serial
vasodilator agents we used a one way repeated
measures analysis of variance (ANOVA), with a post
hoc Tukey test, when F ratios proved to be
significantly increased. Correlation between the
percent change in mPAP and PVR during adminis-
tration of various vasodilators was assessed by
linear regression analysis. A P-value o0.05 was
considered statistically significant.Results
Of 35 patients screened consecutively at Rhode
Island Hospital and Boston Medical Center, 20
patients met the inclusion/exclusion criteria. Pa-
tients’ characteristics, baseline pulmonary function
tests and hemodynamic parameters are presented
in Table 1. Patients were middle aged on average,
mostly females, with class II–IV New York Heart
Association (NYHA) functional classification and
most had severe pulmonary hypertension. Pulmon-
ary functions were within normal limits on average,Table 1 Patient characteristic, baseline pulmonary func
All
No. of patients 20
Age, years 5573
Female 13
NYHA classification II:III:IV 2:17:1
TLC (% predicted) 8574
FEV1/FVC (%) 8474
DLCO (% predicted) 4875
mPAP (mm Hg) 5172
PVR (dyne/s/cm5) 707762
CI (L/min/m2) 2.6070.15
PAWP (mm Hg) 1171
SVR (dyne/s/cm5) 14457697
IPAH ¼ idiopathic pulmonary arterial hypertension; CTD ¼ con
TLC ¼ total lung capacity; FEV1/FVC ¼ forced expiratory volume i
for carbon monoxide; mPAP ¼ mean pulmonary artery pressure
PAWP ¼ pulmonary arterial wedge pressure; SVR ¼ systemic vasc
yOther includes 2 patients with sarcoidosis and one patient wit
zP ¼ 0:004 compared with the IPAH group by 2 way ANOVA.although the CTD group had mild restriction, as
well as a lower diffusing capacity.
During acute vasodilator testing, all patients
received sildenafil, 19 received epoprostenol (the
patient with sickle cell disease refused), and 11
received iNO and sildenafil+iNO (the latter being
patients from Rhode Island Hospital: 7 with idio-
pathic pulmonary arterial hypertension (IPAH), 3
with CTD and one with sarcoidosis) (Fig. 1).
Acute pulmonary hemodynamic responses
Inhaled NO was the most potent of the agents in
reducing mPAP, lowering it by 1974% (Po0:001,
Fig. 2a), whereas epoprostenol and sildenafil had
smaller effects on mPAP (1373%, P ¼ 0:004 and
1473%, P ¼ 0:005, respectively). The addition of
iNO 90min after the last dose of sildenafil, while
the hemodynamic response to sildenafil remained
maximal, further decreased mPAP by 1373%. When
compared with the baseline value, combination
therapy lowered mPAP by 2674% (Po0:001, by
paired analysis), a reduction that was greater than
either epoprostenol or sildenafil alone.
Epoprostenol had the greatest augmenting effect
on CI (increase of 4175%, Po0:001, Fig. 2b),
followed by sildenafil (2475%, P ¼ 0:005). This
suggests that sildenafil, similar to epoprostenol,
has vasodilatory effects on both the pulmonary and
systemic circulations and, possibly, a positive
inotropic effect, contributing to a greater increase
in blood flow. Inhaled NO did not alter CI, either
alone or when it was added to sildenafil.tion tests and hemodynamics.
IPAH CTD Othery
10 7 3
5876 5373 49714
8 4 1
1:8:1 1:6:0 0:3:0
9975 6976z 7671
7276 9275 9978
5779 3575 52710
5274 5074 5172
825797 551771 6817133
2.3470.15 2.9670.32 2.6270.28
1171 1172 1171
15957152 12277127 14507200
nective tissue disease; NYHA ¼ New York Heart Association;
n one second/forced vital capacity; DLCO ¼ diffusion capacity
; PVR ¼ pulmonary vascular resistance; CI ¼ cardiac index;
ular resistance.
h sickle cell disease.
ARTICLE IN PRESS
Epo iNO Sild Sild+iNO
%
 D
ec
re
as
e 
in
 P
VR
-60
-50
-40
-30
-20
-10
767 +  69 752 + 97
528 + 70
733 +  68
512 +  46
782 +  96
465 + 64
460 +  49
p=0.007 p=0.033
p=0.015 p=0.033
*
*
Epo iNO Sild Sild+iNO
%
PV
R/
%
SV
R
-40
-30
-20
-10
0
p=0.018 p=0.027
p=0.02
*
*
(a)
(b)
Figure 3 Responses to vasodilators: percent change from
baseline to maximal for PVR (a), and PVR/SVR ratio (b).
Differences between responses to iNO, sildenafil and
iNO+sildenafil (11 patients) were analyzed by paired t-
tests, while differences between epoprostenol (all
patients) and the other treatment groups (11 patients)
were analyzed by unpaired t-tests. *Indicates Po0:05.
Pre- and post-treatment values are statistically signifi-
cant except for change in PVR/SVR ratio with sildenafil.
Numbers written in each bar represent pre- and post-
treatment absolute values of PVR (dyne/cm/s) (panel a).
For abbreviations, see Table 1 and Fig. 2.
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Figure 2 Responses to vasodilators: percent change from
baseline to maximal for mPAP (a), and CI (b). Differences
between pre- and post-treatment values are statistically
significant by paired t-test in all groups, except for the
change in CI with iNO. Differences between responses to
iNO, sildenafil and iNO+sildenafil (11 patients) were
analyzed by paired t-test, while differences between
epoprostenol (all patients) and the other treatment
groups (11 patients) were analyzed by unpaired t-tests.
*Indicates Po0:05. The numbers written in each bar
represent pre- and post-treatment values of mPAP
(mmHg) (a) and CI (L/min/m2) (b). iNO ¼ inhaled nitric
oxide; Epo ¼ epoprostenol; Sild ¼ sildenafil.
Acute and chronic effects of sildenafil 1505Pulmonary and systemic vascular resistances
Epoprostenol decreased PVR by 3974% (Po0:001,
Fig. 3a), significantly more than iNO or sildenafil
alone (2476% decrease with iNO, P ¼ 0:011 and
2972% decrease with sildenafil, Po0:001 from
baseline). INO added to sildenafil lowered PVR by
an additional 1574% (total 43%). This combination
was more potent than either agent alone
(P ¼ 0:033, by repeated measures analysis), but
not different from epoprostenol.Epoprostenol and sildenafil each lowered mean
systemic blood pressure, from 9173 to 8272mm
Hg (P ¼ 0:023) and from 8974 to 8073mm Hg
(P ¼ 0:048), respectively. INO did not affect mean
systemic blood pressure, either alone (from 9073
to 8873mm Hg, P ¼ ns), or when added to
sildenafil (from 7573 to 7774mm Hg, P ¼ ns).
Furthermore, as indicated by changes in the PVR/
SVR ratio (Fig. 3b), iNO was a specific pulmonary
vasodilator both alone (378%, Po0:001), and
when added to sildenafil (2574%, Po0:001),
whereas PVR/SVR did not change significantly with
either epoprostenol or sildenafil, indicating that
their vasodilator effects were nonspecific.
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Figure 4 Correlations (by linear regression) for maximal decreases in mPAP (left panels) and PVR (right panels) between
the different vasodilators used. The correlations were strongest for iNO and epoprostenol (panels a,b); and weaker for
iNO and sildenafil (panels c,d), and epoprostenol and sildenafil (panels e,f); for abbreviations, see legend for Table 1.
I.R. Preston et al.1506Comparison of acute vasodilator responses
As previously reported,17 the vasodilator responses
of iNO and epoprostenol were strongly correlated,
both with regard to mPAP (Fig. 4a) and PVR
(Fig. 4b). Correlations were weaker for mPAP and
PVR between sildenafil and iNO (Fig. 4c,d) and
sildenafil and epoprostenol (Fig. 3d,e). Although
these correlations were statistically significant
(with the exception of that between sildenafil and
iNO for mPAP), the r2 values were substantially
lower than those for iNO and epoprostenol. In
addition, we present the change in hemodynamicsin the 11 patients that had all 4 vasodilator
challenges (Fig. 5a, b). Seven of the 10 patients
received iNO in the concentration of 10 ppm (all
responders to 10 ppm) and 3 received 20 ppm (one
responder to 20 ppm and 2 nonresponders). The
addition of iNO to sildenafil further decreased both
mean PA pressure and PVR significantly.
Long-term treatment
Table 2 shows ages (mean 58715 years), genders,
pulmonary hypertension diagnoses, concurrent pul-
monary hypertension medications, and functional
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Figure 5 Serial hemodynamic measurements in the 11 patients that had all four vasodilator challenges. BS ¼ baseline.
For rest of abbreviations see Fig. 1. Analysis by one way repeated measures of variance demonstrates statistically
significant differences (Po0:05) between baseline vs. treatment. There was also a statistically significant difference
between sildenafil and sildenafil+iNO (Po0:05).
Table 2 Characteristics of patients who received long-term sildenafil treatment.
Pt Age/sex Diagnosis NYHA
class
Concurrent
medication
Sildenafil dose/day
length of treatment
NYHA class on
sildenafil
Symptoms
improvedy
1 57/M IPAH III Bosentan 150mg/14 months III Yes
2 48/M IPAH IV Epoprostenol 150mg/12 months III Yesz
3 77/F IPAH III — 50mg/7 months III No
4 38/M IPAH III — 400mg/12 months II Yes
5 47/M CTD IV Epoprostenol 150mg/16 months III Yes
6 69/F CTD IV Treprostinil/
Bosentan
150mg/8 months III Yes
7 59/F CTD IV Treprostinil/
Bosentan
150mg/7 months II Yes
8 74/F CTD IV Bosentan 150mg/8 months III Yesz
9 72/M Sarcoid III — 200mg/24 months III Yes
10 38/M HHT III — 200mg/12 months III Yes
IPAH ¼ idiopathic pulmonary arterial hypertension; DM ¼ dermatomyositis; HHT ¼ hereditary hemorrhagic telangiectasia;
CAD ¼ coronary artery disease.
ySymptomatic response was considered an improvement in exercise tolerance as perceived by the patient in daily activities,
exertional chest pain, or lightheadness.
zBoth patients improved for a 12 and 8 months, respectively, after that they decompensated and died of right heart failure.
Acute and chronic effects of sildenafil 1507and symptomatic responses of 10 patients receiving
long-term sildenafil therapy.
Patients #1, 3, 5, 7 and 9 were tested acutely
with sildenafil which lowered their mPAP and PVR
by an average of 2274% and 3072%, respectively.
Four of the five had a significant acute response to
sildenafil (a 20% or more decrease in both mean PAP
and PVR). The remaining patients did not undergo
acute testing with sildenafil because the protocol
was not available at the time of the right heart
catheterization. Sildenafil therapy was initiated fora deteriorating status despite increasing doses of
epoprostenol (patients #2 and 5), bosentan (pa-
tients #1 and 8), or a combination of treprostinil
and bosentan (patients #6 and 7). Patients #3, 4, 9
and 10 refused prostacyclin therapy and bosentan
was not available at the time of initiation of
therapy.
The average length of sildenafil follow-up was
1271.6 months. Six of the 10 patients improved
NYHA functional score by at least one class (Table
2) and nine reported improvement in exertional
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Figure 6 Distances walked in 6min by 9 patients on long-
term sildenafil. Best walk tests on epoprostenol, trepros-
tinil and/or bosentan (Epo/Tre/Bos) are compared with
walk tests just before sildenafil was added to current
therapy (Pre-sildenafil) and with therapy with sildenafil.
*Patients 2 and 8 died after 12 and 8 months,
respectively, after an initial improvement and patient 3
did not improve and died after 7 months.
I.R. Preston et al.1508dyspnea. Patient 3 deteriorated despite sildenafil
treatment and died. Patient 2 and 8 improved for
the first 12 and 8 months, respectively, after which
they slowly decompensated and died of right-sided
heart failure. The remaining 7 patients have
remained symptomatically improved, with an aver-
age follow-up time of 12.572 months. Interest-
ingly, out of the five patients tested acutely with
sildenafil, one acute responder deteriorated with
long-term treatment, while the nonresponder im-
proved rapidly and steadily with long-term treat-
ment. Echocardiograms were obtained before
sildenafil was started and after 2–8 months of
treatment in 7 patients, with no change in
estimated peak systolic pulmonary artery pressures
or right ventricular function (initial mean systolic
PAP was 75712 and follow-up 73719mm Hg,
P ¼ ns). Six minute walk tests declined from
267772m while on treatment with vasodilators
to 191746m before sildenafil was started and
improved to a mean of 250750m with long-term
sildenafil (Po0:05 with one way repeated measures
ANOVA, Fig. 6).Adverse effects
One patient developed substernal chest pain with-
out EKG changes during epoprostenol infusion at
1 ng/kg/min that resolved upon discontinuation of
the infusion. The average total dose of sildenafil
given acutely was 122.5744mg (mean7SD), start-
ing with doses of 25–50mg, depending on age
(see the section
’ ’
Methods’’). During acute vasodi-
lator testing, 3 patients developed asymptomatichypotension after 50mg of sildenafil (systolic sys-
temic blood pressures of 80–85mm Hg) that sponta-
neously resolved within 1–2h. Although it did not
reach statistical significance, these 3 patients had
lower mPAPs and PVRs at baseline than the seven
who did not have a decrease in systemic pressures
(mPAP 4677 vs. 5475mm Hg and PVR 5327119 vs.
7877114 dyne/s/cm5, respectively). Long-term sil-
denafil was well tolerated except in patient #3, who
developed lightheadedness when sildenafil was
increased from 50 to 75mg three times a day. This
symptom resolved after the dose was lowered to
25mg twice a day, but her exertional dyspnea
continued to worsen. Patient #9 had increased
dyspnea on exertion after 6 months of therapy that
improved after the sildenafil dose was increased
from 75 to 100mg twice daily. None of the 10
patients receiving long-term sildenafil experienced
symptomatic systemic hypotension.Discussion
Our findings confirm that the PDE5 inhibitor
sildenafil is an effective acute pulmonary vasodi-
lator and that the addition of iNO, a stimulator of
cGMP production, potentiates the vasodilator ac-
tion of sildenafil. The combination of sildenafil and
iNO lowered PVR more than either agent alone and
was as potent as epoprostenol, but with more
pulmonary selectivity. As previously reported,17
maximal vasodilator responses to epoprostenol
and iNO correlated well, but those of sildenafil
and either epoprostenol or iNO correlated less well.
Finally, in a small cohort of patients, long-term
therapy with sildenafil was well tolerated and
brought about a sustained symptomatic improve-
ment in most patients.
Maclean et al.20 provided the pathophysiologic
rationale for using PDE5 inhibitors as pulmonary
vasodilators by demonstrating the presence of PDE5
activity in pulmonary arteries from normoxic rats
and an increased activity in response to chronic
hypoxia. PDE5 inhibitors have been shown to dilate
pulmonary vessels in pulmonary hypertension mod-
els,21,22 as well as in normal human subjects with
acute hypoxia-induced pulmonary hypertension.11
Subsequently, two studies12,15 reported the effect
of PDE5 inhibition in combination with the inhaled
prostacyclin, iloprost, in patients with PAH. They
demonstrated that oral sildenafil and inhaled
iloprost had similar vasodilator effects, and that
the combination of these two drugs was more
effective than either agent alone. Lastly, in
patients with pulmonary hypertension secondary
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pulmonary vasodilation similar to that of epopros-
tenol, but unlike epoprostenol, sildenafil also
improved gas exchange by maintaining ventila-
tion/perfusion matching.13
In the current study, iNO potentiated the
pulmonary vasodilator effects of sildenafil. This
has previously been shown in an animal model
of acute pulmonary hypertension, in which neb-
ulized sildenafil potentiated the vasodilator
effects of iNO.9 In addition, two case reports
have observed a prolongation of iNO vasodilatory
effects by sildenafil, facilitating weaning from
iNO following cardiac surgery23 and after iNO
therapy of a newborn with persistent pulmonary
hypertension.24
Our study results are also similar to those of
Michelakis et al.,14 who found that in patients with
severe pulmonary hypertension, the combination of
sildenafil and iNO brought about more vasodilation
than iNO alone, but not significantly more than
75mg of sildenafil alone, and that cGMP levels
increased synergistically with combined therapy. In
our study, combination therapy was more potent
than either vasodilator alone in decreasing PVR.
This difference between our results and those of
Michelakis et al.14 may reside in the different
populations studied (IPAH, PAH associated with left
ventricular dysfunction, atrial septal defect, or
cirrhosis in Michelakis study), and in differing
dosing regimens between the studies, with our
patients receiving higher doses of sildenafil, on
average.
As previously reported by Sitbon et al.,17 we
found that acute pulmonary vasodilator responses
to iNO and epoprostenol were highly correlated. In
contrast to their utility in predicting calcium
channel blocker responsiveness,25 however, vasodi-
lator responsiveness to iNO and epoprostenol in our
study correlated relatively poorly with that to
sildenafil, indicating that they are of limited
usefulness in predicting acute vasoresponsiveness
to sildenafil and raising questions about their ability
to predict long-term responsiveness to sildenafil. Of
course, whether acute vasodilator responses even
to sildenafil predict long-term success with the
drug is currently unknown. In addition, the patterns
of vasoresponsiveness differed between the agents,
with iNO acting as a selective pulmonary vasodi-
lator, lowering mPAP but not affecting cardiac
output or systemic blood pressure. Sildenafil and
epoprostenol, on the other hand, acted as non-
selective vasodilators, with significant effects not
only on mPAP, but also on cardiac output and
systemic blood pressure. Adding iNO to sildenafil
restored pulmonary selectivity and effected great-er pulmonary vasodilation than with either agent
alone.
Based on our experience, long-term treatment
with sildenafil holds promise. Nine of our 10
patients treated long-term tolerated the therapy
well and experienced symptomatic and functional
improvement, as evidenced by increases in the
6min walk distance. In addition, NYHA functional
class improved in 6 patients. The combination of
sildenalfil and a prostacyclin (2 patients), or the
nonselective endothelin receptor blocker, bosentan
(2 patients), or all 3 drugs together (2 patients) was
also well tolerated. Whether tolerance develops to
sildenafil as it does to infused prostacyclins is
unclear, but the worsening of symptoms experi-
enced by patient #9 after 6 months of therapy that
was promptly reversed after the sildenafil dose was
increased raises this possibility. A report on
patients using sildenafil regularly for erectile
dysfunction, who had to increase their doses after
the first few months to maintain a therapeutic
response is consistent with this view.26
Whether the progressive deterioration and
deaths of 3 of our patients, two after initial
improvement, are related to tolerance or recalci-
trant disease in some patients is unclear from our
results, but this experience does indicate that
sustained responsiveness to sildenafil is not uni-
versal. On the other hand, sildenafil effected
sustained symptomatic improvement in 7 of our
patients for an average follow-up period exceeding
one year, the longest yet reported, and suggesting
that the drug achieves durable benefit in the
majority of patients. The lack of improvement on
follow-up echocardiograms despite symptomatic
improvement may be explained by an increase in
cardiac output without a corresponding drop in PA
pressure, phenomenon that is not detected by
echocardiogram.
Our demonstration that sildenafil and iNO have
synergistic and pulmonary selective vasodilator
effects, along with the previous reports on combi-
nations of sildenafil and other agents,12,15 raises
the distinct possibility that combination vasodilator
therapy may be more effective for the manage-
ment of pulmonary hypertension than single agent
therapy. Whether it is better to combine agents
that act via a single second messenger pathway,
such as is the case with sildenafil and iNO via cGMP,
or via different signaling pathways, such as
sildenafil in combination with prostacyclins or
endothelin receptor antagonists, remains to be
seen. Also, whether the additive effects of iNO and
sildenafil are related only to potentiation of
increases in intracellular cGMP levels, or whether
PDE5 inhibition produces vasodilation by increasing
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cross-talking’’,27 awaits further study.
We conclude that sildenafil is a potent acute
pulmonary vasodilator for patients with different
forms of PAH, with acute hemodynamic effects
similar to those of epoprostenol. The combination
of iNO and sildenafil has more potent acute
vasodilatory effects than either agent alone.
Because acute vasodilator testing with sildenafil
may cause transient systemic hypotension in some
patients with PAH, use of lower doses (i.e. 25mg)
and careful monitoring of systemic blood pressure
is recommended during initiation. For long-term
use, sildenafil is well tolerated both singly and in
combination and improves symptoms in most
patients, but further study is needed to determine
its long-term effects on pulmonary hemodynamics
and functional capacity and how long beneficial
effects are sustained.References
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